$KTTA
Pasithea Therapeutics Corp. Stock $ktta

$ktta Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023024755 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$240.7K	$486.6K
YoY Change	-100.0%	1498.34%	3130.8%
Cost Of Revenue		-$1.310K	$113.2K
YoY Change		-107.58%	555.06%
Gross Profit		$242.0K	$373.4K
YoY Change		-11001.8%	-16918.2%
Gross Profit Margin		100.54%	76.74%
Selling, General & Admin	$2.116M	$3.936M	$12.52M
YoY Change	-12.02%	101.45%	178.0%
% of Gross Profit		1626.47%	3354.44%
Research & Development	$1.096M	$1.387M	$2.665M
YoY Change
% of Gross Profit		572.89%	713.9%
Depreciation & Amortization	$4.179K	-$100.00	$31.52K
YoY Change	-16.59%	-107.25%	2184.06%
% of Gross Profit		-0.04%	8.44%
Operating Expenses	$3.213M	$5.323M	$15.19M
YoY Change	33.56%	172.4%	237.16%
Operating Profit	-$3.213M	-$5.081M	-$14.82M
YoY Change	33.6%	159.72%	228.71%
Interest Expense	$6.388K	$980.4K	$102.00
YoY Change	-99.19%	-62.09%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$50.00K	-$280.00	$311.0K
YoY Change	-211.11%	1300.0%	-86.68%
Pretax Income	-$3.266M	-$5.118M	-$13.94M
YoY Change	107.45%	-912.18%	541.19%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.538M	-$5.118M	-$13.94M
YoY Change	124.72%	-912.18%	541.19%
Net Earnings / Revenue		-2126.08%	-2864.29%
Basic Earnings Per Share	-$0.01		-$0.55
Diluted Earnings Per Share	-$0.01	-$0.18	-$0.53
COMMON SHARES
Basic Shares Outstanding	26.13M shares	29.25M shares	25.25M shares
Diluted Shares Outstanding	26.07M shares		25.25M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.91M	$33.15M	$33.15M
YoY Change	-40.55%	-37.42%	-37.42%
Cash & Equivalents	$29.91M	$33.15M
Short-Term Investments
Other Short-Term Assets	$263.0K	$302.1K	$627.7K
YoY Change	-58.17%		88.07%
Inventory
Prepaid Expenses	$835.8K	$627.7K
Receivables
Other Receivables	$15.78K
Total Short-Term Assets	$31.11M	$34.08M	$34.08M
YoY Change	-38.93%	-36.07%	-36.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$174.9K	$378.8K	$1.253M
YoY Change	35.99%	1782.25%	6128.88%
Goodwill	$1.263M	$1.263M
YoY Change
Intangibles	$8.414M	$8.587M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$619.3K
YoY Change
Total Long-Term Assets	$10.93M	$11.10M	$11.10M
YoY Change	8399.13%	55074.9%	55085.88%
TOTAL ASSETS
Total Short-Term Assets	$31.11M	$34.08M	$34.08M
Total Long-Term Assets	$10.93M	$11.10M	$11.10M
Total Assets	$42.04M	$45.18M	$45.18M
YoY Change	-17.69%	-15.27%	-15.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.448M	$1.614M	$1.614M
YoY Change	233.78%	260.92%	260.92%
Accrued Expenses	$165.0K	$263.3K	$263.3K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$264.1K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.122M	$1.878M	$1.878M
YoY Change	389.34%	319.79%	319.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$787.6K	$804.2K	$804.2K
YoY Change	18.0%	-44.64%	-44.64%
Total Long-Term Liabilities	$787.6K	$804.2K	$804.2K
YoY Change	18.0%	-44.64%	-44.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.122M	$1.878M	$1.878M
Total Long-Term Liabilities	$787.6K	$804.2K	$804.2K
Total Liabilities	$2.910M	$2.682M	$2.682M
YoY Change	164.24%	41.14%	41.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.89M	-$19.36M
YoY Change		774.1%
Common Stock	$18.00K	$17.99K
YoY Change		1.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares		2.700M shares
Shareholders Equity	$39.14M	$42.50M	$42.50M
YoY Change
Total Liabilities & Shareholders Equity	$42.04M	$45.18M	$45.18M
YoY Change	-17.69%	-15.27%	-15.27%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.538M	-$5.118M	-$13.94M
YoY Change	124.72%	-912.18%	541.19%
Depreciation, Depletion And Amortization	$4.179K	-$100.00	$31.52K
YoY Change	-16.59%	-107.25%	2184.06%
Cash From Operating Activities	-$3.386M	-$4.419M	-$14.56M
YoY Change	33.96%	153.32%	358.78%
INVESTING ACTIVITIES
Capital Expenditures	$53.89K	$1.789M	$374.9K
YoY Change	-147.32%	-13935.96%	-1843.67%
Acquisitions			-$77.06K
YoY Change
Other Investing Activities	$4.190K	$32.98K	$77.06K
YoY Change
Cash From Investing Activities	-$49.70K	-$1.756M	-$2.062M
YoY Change	-56.35%	13480.82%	9488.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	264.1K	-3.206M	-$3.206M
YoY Change		-109.38%	-105.73%
NET CHANGE
Cash From Operating Activities	-3.386M	-4.419M	-$14.56M
Cash From Investing Activities	-49.70K	-1.756M	-$2.062M
Cash From Financing Activities	264.1K	-3.206M	-$3.206M
Net Change In Cash	-$3.174M	-9.381M	-$19.82M
YoY Change		-128.95%	-137.58%
FREE CASH FLOW
Cash From Operating Activities	-$3.386M	-$4.419M	-$14.56M
Capital Expenditures	$53.89K	$1.789M	$374.9K
Free Cash Flow	-$3.440M	-$6.208M	-$14.94M
YoY Change	42.51%	258.54%	373.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40804
CY2022	dei	Entity Registrant Name EntityRegistrantName	PASITHEA THERAPEUTICS CORP.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1591963
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Lincoln Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami Beach
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33139
CY2022	dei	City Area Code CityAreaCode	(702)
CY2022	dei	Local Phone Number LocalPhoneNumber	514-4174
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	KTTA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	19400000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26126740	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum llp
CY2022	dei	Auditor Location AuditorLocation	New Haven, CT
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33146895	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52966706	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	627666	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	333751	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	302132	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	34076693	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	53300457	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	378783	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20124	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	874463	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8587239	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1262911	usd
CY2022Q4	us-gaap	Assets Assets	45180089	usd
CY2021Q4	us-gaap	Assets Assets	53320581	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1614343	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	447280	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	263291	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1877634	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	447280	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	663596	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	140611	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1452800	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	804207	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1452800	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2681841	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1900080	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	495000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	495000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26043406	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26043406	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23008371	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23008371	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	17987	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17684	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61837802	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53627883	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-661	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10561	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19356880	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2214505	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	42498248	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51420501	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45180089	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53320581	usd
CY2022	us-gaap	Revenues Revenues	486559	usd
CY2021	us-gaap	Revenues Revenues	15062	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	113195	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17275	usd
CY2022	ktta	Grant Incomes GrantIncomes	373364	usd
CY2021	ktta	Grant Incomes GrantIncomes	-2213	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12524258	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4505200	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2665427	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-14816321	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-4507413	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1852189	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2334400	usd
CY2022	us-gaap	Interest Expense InterestExpense	102	usd
CY2021	us-gaap	Interest Expense InterestExpense	508	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	44723	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1016941	usd
CY2022	us-gaap	Other Income OtherIncome	879869	usd
CY2021	us-gaap	Other Income OtherIncome	2333892	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13936452	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2173521	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13936452	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2173521	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25251756	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10404668	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13936452	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2173521	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9900	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-10561	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13926552	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2184082	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	241355	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	471250	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1208926	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	750000	usd
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3600000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	187200	usd
CY2021	ktta	Stock Issued During Period Value Netof Underwriting Discountsand Offering Costs StockIssuedDuringPeriodValueNetofUnderwritingDiscountsandOfferingCosts	20554800	usd
CY2021	ktta	Sale Of Common Stock And Warrants Net Of Fees And Costs SaleOfCommonStockAndWarrantsNetOfFeesAndCosts	27165452	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-10561	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2173521	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51420501	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	552823	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	282241	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3973479	usd
CY2022	ktta	Common Shares And Warrants Issued For Acquisition Of Intangible Assets CommonSharesAndWarrantsIssuedForAcquisitionOfIntangibleAssets	3402000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	3206244	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	9900	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13936452	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	42498248	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13936452	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2173521	usd
CY2022	us-gaap	Depreciation Depreciation	31520	usd
CY2021	us-gaap	Depreciation Depreciation	1379	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	552823	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	471250	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	282241	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	750000	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-1852189	usd
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-2334400	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	854	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	423412	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	74309	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	244535	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	329443	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	725544	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	831640	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	440677	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14561921	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3174058	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	374889	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21503	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-77060	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1763717	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2061546	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21503	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1208926	usd
CY2021	ktta	Cash Proceeds From Sale Of Units CashProceedsFromSaleOfUnits	21862200	usd
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	27165452	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7000000	usd
CY2021	ktta	Payment Of Offering Costs PaymentOfOfferingCosts	-1307400	usd
CY2022	ktta	Repurchase Of Shares In Litigation Settlement RepurchaseOfSharesInLitigationSettlement	-3206244	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3206244	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55929178	usd
CY2022	ktta	Effect Of Foreign Currency Translation On Cash EffectOfForeignCurrencyTranslationOnCash	9900	usd
CY2021	ktta	Effect Of Foreign Currency Translation On Cash EffectOfForeignCurrencyTranslationOnCash	-10561	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19819811	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52723056	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52966706	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243650	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33146895	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52966706	usd
CY2022	ktta	Equity Purchase Consideration For Acquired Business EquityPurchaseConsiderationForAcquiredBusiness	3973479	usd
CY2022	ktta	Equity Purchase Consideration For Acquired Intangible Assets EquityPurchaseConsiderationForAcquiredIntangibleAssets	3402000	usd
CY2022	ktta	Lease Liabilities Arising From Obtaining Rightofuse Assets LeaseLiabilitiesArisingFromObtainingRightofuseAssets	926887	usd
CY2021	ktta	Initial Recording Of Warrant Liabilities InitialRecordingOfWarrantLiabilities	3787200	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	33100000	usd
CY2022Q4	ktta	Working Capital Amount WorkingCapitalAmount	32200000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Management regularly makes estimates related to the fair value of warrant liabilities; the recoverability of long-lived assets; the fair values and useful lives of intangible assets acquired in business combinations; the potential impairment of goodwill; and income taxes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable, the results of which form the basis for the amounts recorded in the consolidated financial statements. As appropriate, the Company obtains reports from third-party valuation experts to inform and support estimates related to fair value measurements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	ktta	Grant Income To Related Party GrantIncomeToRelatedParty	200000	usd
CY2021Q3	ktta	Offering Costs OfferingCosts	3445200	usd
CY2021Q3	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	2137800	usd
CY2021Q3	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1307400	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentration of Credit Risk</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of December 31, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	ktta	Payments In Advance PaymentsInAdvance	1	pure
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.30	pure
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	1.2039	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	1.348	pure
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	1.2362	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	1.371	pure
CY2022Q4	ktta	Foreign Currency Exchange Rate Remeasurements ForeignCurrencyExchangeRateRemeasurements	0.9367	pure
CY2021Q4	ktta	Foreign Currency Exchange Rate Remeasurements ForeignCurrencyExchangeRateRemeasurements	1.132	pure
CY2022Q4	ktta	Foreign Currency Exchange Rate Translation ForeignCurrencyExchangeRateTranslation	0.9517	pure
CY2021Q4	ktta	Foreign Currency Exchange Rate Translation ForeignCurrencyExchangeRateTranslation	1.143	pure
CY2021	us-gaap	Depreciation Depreciation	1379	usd
CY2021Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	20600000	usd
CY2022	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	Each Unit consisted of one share of Common Stock and one Public Warrant. The Common Stock and Public Warrants are listed on The Nasdaq Capital Market under the symbols “KTTA” and “KTTAW,” respectively. Each redeemable Public Warrant entitles the holder to immediately purchase one share of Common Stock at an exercise price of $6.25 per share, and expire five years from issuance.
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	720000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	720000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	720000	shares
CY2021Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.01
CY2021Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	7200	usd
CY2021Q4	ktta	Common Stock Lapsed CommonStockLapsed	720000	shares
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	409801000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	21503000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	31018000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	1379000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Owned Net PropertyPlantAndEquipmentOwnedNet	378783000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Owned Net PropertyPlantAndEquipmentOwnedNet	20124000	usd
CY2022	us-gaap	Depreciation Depreciation	31520	usd
CY2022Q2	us-gaap	Lessee Finance Lease Description LesseeFinanceLeaseDescription	The lease has a 60-month term, and the Company has an option to extend the term for one 5-year renewal period at the prevailing market rate that the landlord is then obtaining from tenants for comparable space in the building. The lease has a base monthly rent of $8,336 per month for the first 12 months, with the base monthly rent increasing by 4% on the first anniversary of the lease commencement date and every 12 months thereafter. In addition to the base monthly rent, commencing on the first anniversary of the lease commencement date, the Company will pay its share of certain direct operating and tax expenses incurred by the landlord in maintaining the building.
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	431000	usd
CY2022Q4	us-gaap	General Fair Value Hedge Information Minimum R Square Percentage GeneralFairValueHedgeInformationMinimumRSquarePercentage	0.078	pure
CY2022	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	15700	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	569000	usd
CY2022Q4	us-gaap	Percentage Of Debt Hedged By Interest Rate Derivatives PercentageOfDebtHedgedByInterestRateDerivatives	0.078	pure
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	874463	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	263291	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	663596	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	244004	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	169695	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	297575	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	307026	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	294657	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	115899	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	29256	usd
CY2022Q2	ktta	Purchase Agreement Percentage PurchaseAgreementPercentage	1	pure
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3260870	shares
CY2022Q2	ktta	Market Value MarketValue	1.01
CY2022Q2	us-gaap	Common Stock Discount On Shares CommonStockDiscountOnShares	1000000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.88
CY2022Q2	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P5Y
CY2022Q2	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	400000	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable	3293479	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	680000	usd
CY2022	us-gaap	Business Combination Price Of Acquisition Expected BusinessCombinationPriceOfAcquisitionExpected	3973479	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	77060	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	49380	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	19551	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2900000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	335423	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	2710568	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1262911	usd
CY2022	us-gaap	Other Expenses OtherExpenses	311000	usd
CY2022Q4	ktta	Company Acquired CompanyAcquired	1	pure
CY2022Q4	ktta	Asset Acquisition Description AssetAcquisitionDescription	(i) an aggregate of 2,700,000 shares of Common Stock, (ii) an aggregate of 1,000,000 warrants to purchase shares of Common Stock at an exercise price of $1.88 per share, which may be exercised on a cashless basis, for a period of five years commencing on the date of issuance, (iii) a cash payment in the amount of $1,050,000, (iv) the right to certain milestone payments in an amount up to $5,000,000, and (v) the right to contingent earn-out payments ranging from 3% to 5% of net sales of the drug depending on the amount of such net sales in the applicable measurement period.
CY2022	ktta	Restrictions Agreements RestrictionsAgreements	1350000	shares
CY2022	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	112500	shares
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2700000	shares
CY2022Q4	ktta	Shares Of Pasithea Common Stock SharesOfPasitheaCommonStock	3402000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000	shares
CY2022	ktta	Common Stock At Exercise Price CommonStockAtExercisePrice	1.88
CY2022	ktta	Warrants To Acquire Shares Of Common Stock WarrantsToAcquireSharesOfCommonStock	522358	usd
CY2022Q4	us-gaap	Cash Cash	1000000	usd
CY2022	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	50000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	697121	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	5671479	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	630134	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	630134	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	630134	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	630134	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	630134	usd
CY2022	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	1300000	usd
CY2022Q4	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	500000000	shares
CY2022	ktta	Description Of Authorized Capital Stock DescriptionOfAuthorizedCapitalStock	The authorized capital stock is divided into: (i) 495,000,000 shares of Common Stock having a par value of $0.0001 per share and (ii) 5,000,000 shares of preferred stock having a par value of $0.0001 per share.
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2021	ktta	Increase To Equal Percentage IncreaseToEqualPercentage	0.03	pure
CY2022	ktta	Aggregate Of Stock Options Under AggregateOfStockOptionsUnder	800000	shares
CY2021	ktta	Aggregate Of Stock Options Under AggregateOfStockOptionsUnder	600000	shares
CY2022Q4	ktta	Total Shares TotalShares	1966483	shares
CY2022	ktta	Potential Issuances Shares PotentialIssuancesShares	466483	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.6
CY2022	ktta	Shares Issued1 SharesIssued1	395625	shares
CY2022	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	633000	usd
CY2021	ktta	Additional Shares AdditionalShares	153652	shares
CY2021	ktta	Gross Proceeds GrossProceeds	7000000	usd
CY2021Q4	ktta	Cash Fee CashFee	0.09	pure
CY2021Q4	ktta	Accountable Expenses AccountableExpenses	70000	usd
CY2021Q4	ktta	Shares Per Shares SharesPerShares	8680000	shares
CY2021Q4	ktta	Purchase To Warrants PurchaseToWarrants	8680000	shares
CY2021Q4	ktta	Offering Price Per OfferingPricePer	3.5
CY2021Q4	ktta	Aggregate Gross Proceeds AggregateGrossProceeds	30400000	usd
CY2021Q4	ktta	Underwriter Discounts And Fees UnderwriterDiscountsAndFees	27000000	usd
CY2022Q4	ktta	Shares Issued1 SharesIssued1	2700000	shares
CY2022Q4	ktta	Purchased Shares Of Common Stock PurchasedSharesOfCommonStock	3205282	shares
CY2022Q4	ktta	Price Per Share PricePerShare	1.0003
CY2022Q4	ktta	Certain Fees And Expenses CertainFeesAndExpenses	698000	usd
CY2022	us-gaap	Other Comprehensive Income Finalization Of Pension And Non Pension Postretirement Plan Valuation Tax OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax	300000	usd
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	288000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	66667	shares
CY2021	ktta	Additionalpaidin Capital And Compensation Expenses AdditionalpaidinCapitalAndCompensationExpenses	152000	usd
CY2022	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	150000	shares
CY2022	ktta	Shares Of Common Stock SharesOfCommonStock	400000	shares
CY2022	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P2Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	180000	usd
CY2022	ktta	Shares Cancelled Strike Price SharesCancelledStrikePrice	5
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	440000	usd
CY2021	ktta	Shares Of Common Stock SharesOfCommonStock	100000	shares
CY2021Q4	ktta	Common Stock Par Value Per Share CommonStockParValuePerShare	5
CY2021	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P10Y
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	142000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	600000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	600000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.31
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y8M26D
CY2021	ktta	Share Based Compensations Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsExercisableNumber	100000	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y8M15D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	600000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.31
CY2022	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P9Y8M26D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	800000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.1
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	100000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1300000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.28
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y1M13D
CY2022	ktta	Share Based Compensations Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsExercisableNumber	216667	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.6
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y8M15D
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	641181	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.405	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.483	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.033	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.013	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.1
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.47
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.5
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.37
CY2022Q4	ktta	Exercised Price Per Share ExercisedPricePerShare	1.88
CY2022Q4	us-gaap	Shares Issued SharesIssued	1000000	shares
CY2022Q2	ktta	Exercised Price Per Share ExercisedPricePerShare	1.88
CY2022	ktta	Share Based Compensations Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationsArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.557	pure
CY2022	ktta	Share Based Compensation Arrangement By Share Based Payment Award Fair Values Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuesAssumptionsRiskFreeInterestRate	0.0338	pure
CY2021Q4	ktta	Exercised Price Per Share ExercisedPricePerShare	3.5
CY2021Q4	us-gaap	Shares Issued SharesIssued	5520000	shares
CY2021Q4	ktta	Underwriters Shares Issued UnderwritersSharesIssued	276000	shares
CY2022	ktta	Exercised Price Per Share ExercisedPricePerShare	6
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	276000	shares
CY2022	ktta	Fair Value Of Representative Warrants FairValueOfRepresentativeWarrants	0.031
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1120000	shares
CY2021	ktta	Exercised Price Per Share ExercisedPricePerShare	6.25
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7000000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	276000	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	15356000	shares
CY2022	ktta	Weightedaverage Remaining Contractual Termyears WeightedaverageRemainingContractualTermyears	P3Y11M8D
CY2022	ktta	Weightedaverage Exercise Price WeightedaverageExercisePrice	4.12
CY2022Q4	ktta	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	8000	usd
CY2021Q4	ktta	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	11000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	592000	usd
CY2022Q4	ktta	Deferred Tax Assets Rou Asset DeferredTaxAssetsROUAsset	6000	usd
CY2022Q4	ktta	Deferred Tax Assets Warrant Liabilities DeferredTaxAssetsWarrantLiabilities	33000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	303000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	3213000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	920000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4155000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	931000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	12000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	931000	usd
CY2022Q4	ktta	Net Deferred Tax Asset NetDeferredTaxAsset	4143000	usd
CY2021Q4	ktta	Net Deferred Tax Asset NetDeferredTaxAsset	931000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4143000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	931000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3212000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3212000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	931000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	931000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.008	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.061	pure
CY2021	ktta	Effective Income Tax Rate Reconciliation Change Shares Issued For Services EffectiveIncomeTaxRateReconciliationChangeSharesIssuedForServices	-0.097	pure
CY2021	ktta	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	0.301	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.016	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.042	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.244	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.423	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	14500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	7300000	usd
CY2022	ktta	Extinguishment Of Debt Gain Loss Per Share Net ExtinguishmentOfDebtGainLossPerShareNet	15356000	shares
CY2022	ktta	Outstanding Warrant OutstandingWarrant	1300000	shares
CY2021	ktta	Extinguishment Of Debt Gain Loss Per Share Net ExtinguishmentOfDebtGainLossPerShareNet	13356000	shares
CY2021	ktta	Outstanding Warrant OutstandingWarrant	600000	shares
CY2022	us-gaap	Revenues Revenues	486559	usd
CY2021	us-gaap	Revenues Revenues	15062	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13936452	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2173521	usd
CY2022Q2	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	1010000.00	usd
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1000000	shares
CY2022Q2	us-gaap	Share Price SharePrice	1.88
CY2022Q2	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	400000	usd
CY2022	ktta	Revenues Percentage RevenuesPercentage	0.30	pure
CY2022	us-gaap	Related Party Costs RelatedPartyCosts	7500	usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	25000	shares
CY2022	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	100000	shares
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2021	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization		usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	ktta	Cash Proceeds From Sale Of Units CashProceedsFromSaleOfUnits		usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	ktta	Payment Of Offering Costs PaymentOfOfferingCosts		usd
CY2021	ktta	Repurchase Of Shares In Litigation Settlement RepurchaseOfSharesInLitigationSettlement		usd
CY2021	ktta	Equity Purchase Consideration For Acquired Business EquityPurchaseConsiderationForAcquiredBusiness		usd
CY2021	ktta	Equity Purchase Consideration For Acquired Intangible Assets EquityPurchaseConsiderationForAcquiredIntangibleAssets		usd
CY2021	ktta	Lease Liabilities Arising From Obtaining Rightofuse Assets LeaseLiabilitiesArisingFromObtainingRightofuseAssets		usd
CY2022	ktta	Initial Recording Of Warrant Liabilities InitialRecordingOfWarrantLiabilities		usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2021	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm
CY2021Q4	ktta	Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Cancelled Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredCancelledWeightedAverageRemainingContractualTerm
CY2021Q4	ktta	Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Expired Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueExpiredCancelled		usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Cancelled Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredCancelledWeightedAverageRemainingContractualTerm
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2021Q4	ktta	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1		usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm
CY2022Q4	ktta	Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueGranted		usd
CY2022	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Cancelled Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredCancelledWeightedAverageRemainingContractualTerm
CY2022Q4	ktta	Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value Expired Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueExpiredCancelled		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	ktta	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Cancelled Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredCancelledWeightedAverageRemainingContractualTerm
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022Q4	ktta	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts		usd
CY2021Q4	ktta	Deferred Tax Assets Rou Asset DeferredTaxAssetsROUAsset		usd
CY2021Q4	ktta	Deferred Tax Assets Warrant Liabilities DeferredTaxAssetsWarrantLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	ktta	Effective Income Tax Rate Reconciliation Change Shares Issued For Services EffectiveIncomeTaxRateReconciliationChangeSharesIssuedForServices		pure
CY2022	ktta	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities		pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001841330

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-024755-index-headers.html	Edgar Link	pending
0001213900-23-024755-index.html	Edgar Link	pending
0001213900-23-024755.txt	Edgar Link	pending
0001213900-23-024755-xbrl.zip	Edgar Link	pending
f10k2022ex21-1_pasitheathera.htm	Edgar Link	pending
f10k2022ex23-1_pasitheathera.htm	Edgar Link	pending
f10k2022ex3-2_pasitheathera.htm	Edgar Link	pending
f10k2022ex31-1_pasitheathera.htm	Edgar Link	pending
f10k2022ex31-2_pasitheathera.htm	Edgar Link	pending
f10k2022ex32-1_pasitheathera.htm	Edgar Link	pending
f10k2022ex32-2_pasitheathera.htm	Edgar Link	pending
f10k2022ex4-4_pasitheathera.htm	Edgar Link	pending
f10k2022_pasitheathera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
ktta-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
ktta-20221231_cal.xml	Edgar Link	unprocessable
ktta-20221231_def.xml	Edgar Link	unprocessable
ktta-20221231_pre.xml	Edgar Link	unprocessable
ktta-20221231_lab.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
f10k2022_pasitheathera_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KTTA
Pasithea Therapeutics Corp. Stock $ktta

2023 Q1 Form 10-K Financial Statement

#000121390023024755 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KTTA Pasithea Therapeutics Corp. Stock $ktta

2023 Q1 Form 10-K Financial Statement

#000121390023024755 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KTTA
Pasithea Therapeutics Corp. Stock $ktta